256 related articles for article (PubMed ID: 24027308)
21. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter.
Sun CC; Thorley-Lawson DA
J Virol; 2007 Dec; 81(24):13566-77. PubMed ID: 17898050
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
Tierney RJ; Steven N; Young LS; Rickinson AB
J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
[TBL] [Abstract][Full Text] [Related]
24. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.
Hergenhahn M; Soto U; Weninger A; Polack A; Hsu CH; Cheng AL; Rösl F
Mol Carcinog; 2002 Mar; 33(3):137-45. PubMed ID: 11870879
[TBL] [Abstract][Full Text] [Related]
25. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
26. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
27. Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression.
Yang EV; Webster Marketon JI; Chen M; Lo KW; Kim SJ; Glaser R
Brain Behav Immun; 2010 Oct; 24(7):1089-96. PubMed ID: 20466055
[TBL] [Abstract][Full Text] [Related]
28. EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.
Riley KJ; Rabinowitz GS; Yario TA; Luna JM; Darnell RB; Steitz JA
EMBO J; 2012 May; 31(9):2207-21. PubMed ID: 22473208
[TBL] [Abstract][Full Text] [Related]
29. Quantitative and qualitative RNA-Seq-based evaluation of Epstein-Barr virus transcription in type I latency Burkitt's lymphoma cells.
Lin Z; Xu G; Deng N; Taylor C; Zhu D; Flemington EK
J Virol; 2010 Dec; 84(24):13053-8. PubMed ID: 20943983
[TBL] [Abstract][Full Text] [Related]
30. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
31. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus co-opts TFIIH component XPB to specifically activate essential viral lytic promoters.
Verma D; Church TM; Swaminathan S
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13044-13055. PubMed ID: 32434920
[TBL] [Abstract][Full Text] [Related]
33. Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters.
Dickerson SJ; Xing Y; Robinson AR; Seaman WT; Gruffat H; Kenney SC
PLoS Pathog; 2009 Mar; 5(3):e1000356. PubMed ID: 19325883
[TBL] [Abstract][Full Text] [Related]
34. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
35. Latency of Epstein-Barr virus is stabilized by antisense-mediated control of the viral immediate-early gene BZLF-1.
Prang N; Wolf H; Schwarzmann F
J Med Virol; 1999 Dec; 59(4):512-9. PubMed ID: 10534735
[TBL] [Abstract][Full Text] [Related]
36. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).
Fuentes-Pananá EM; Swaminathan S; Ling PD
J Virol; 1999 Jan; 73(1):826-33. PubMed ID: 9847397
[TBL] [Abstract][Full Text] [Related]
38. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
39. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells.
Seto E; Moosmann A; Grömminger S; Walz N; Grundhoff A; Hammerschmidt W
PLoS Pathog; 2010 Aug; 6(8):e1001063. PubMed ID: 20808852
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
